Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies

NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been dosed with AUTX-703 in a first-in-human, Phase 1 clinical trial for patients with advanced hematologic malignancies (NCT06846606).

AUTX-703 is a novel, first-in-class, orally available KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data demonstrating a dose dependent survival advantage with AUTX-703 in a primary acute myeloid leukemia (AML) model.

“The initiation of our first Phase 1 trial marks a significant milestone for Auron in our transition to a clinical-stage company,” said Kate Yen, Chief Executive Officer of Auron Therapeutics. “This achievement reflects the strength of our scientific platform and the dedication of our team in advancing a novel therapeutic approach targeting KAT2A/B – the epigenetic regulators that play a central role in driving cellular plasticity. By modulating this key mechanism, we aim to overcome one of the fundamental barriers to durable cancer treatment. We believe this strategy has the potential to deliver transformative benefits to patients while creating long-term value for our stakeholders.”

“We are excited to initiate this Phase 1 clinical trial of AUTX-703 in advanced hematologic malignancies,” said Dr. Stephen Strickland, Director of Leukemia Research for Sarah Cannon Research Institute (SCRI). “There remains a critical unmet need for novel targeted therapies in acute myeloid leukemia, particularly one with the potential to benefit a broad patient population. With its differentiated mechanism of action and promising preclinical data, AUTX-703 represents a compelling opportunity to advance treatment options in AML, and we look forward to evaluating its potential in the clinic.”

The trial is a Phase 1, open label, dose escalation and dose optimization study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 in patients with relapsed/refractory AML or myelodysplastic syndromes (MDS).

About AUTX-703

AUTX-703 is a first-in-class, oral KAT2A/B degrader, being developed for the treatment of multiple tumor types. Leveraging its AURIGIN™ platform, the Company identified KAT2A/B as a key driver of cell plasticity and disease. KAT2A/B are lysine acetyltransferases that epigenetically reprogram cells to a more proliferative and plastic cell state to drive disease. Auron has validated the target in several disease models including acute myeloid leukemia (AML), small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC). AUTX-703 has cleared two INDs and is in a Phase 1 study in relapsed / refractory (r/r) AML and myelodysplastic syndromes (MDS). In addition, the FDA granted Fast Track designation to AUTX-703 for the treatment of r/r AML.

About Auron Therapeutics

Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit aurontx.com and follow us on LinkedIn.

Investor Contact:

Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

Media Contact:

Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.